[HTML][HTML] Economic analysis of first-line treatment with erlotinib in an EGFR-mutated population with advanced NSCLC
A Vergnenegre, B Massuti, F de Marinis… - Journal of Thoracic …, 2016 - Elsevier
Introduction The cost-effectiveness of first-line tyrosine kinase inhibitor therapy in epidermal
growth factor receptor gene (EGFR)-mutated advanced-stage non–small cell lung cancer …
growth factor receptor gene (EGFR)-mutated advanced-stage non–small cell lung cancer …
Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC
A Vergnenegre, B Massuti, F de Marinis… - Journal of Thoracic …, 2016 - jto.org
Introduction The cost-effectiveness of first-line tyrosine kinase inhibitor therapy in epidermal
growth factor receptor gene (EGFR)-mutated advanced-stage non–small cell lung cancer …
growth factor receptor gene (EGFR)-mutated advanced-stage non–small cell lung cancer …
Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.
A Vergnenegre, B Massuti, F de Marinis… - Journal of Thoracic …, 2016 - europepmc.org
Methods The European Erlotinib versus Chemotherapy study was a multicenter, open-label,
randomized phase III trial performed mainly in Spain, France, and Italy. We based our …
randomized phase III trial performed mainly in Spain, France, and Italy. We based our …
Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC
A Vergnenegre, B Massuti… - Journal of thoracic …, 2016 - pubmed.ncbi.nlm.nih.gov
Introduction The cost-effectiveness of first-line tyrosine kinase inhibitor therapy in epidermal
growth factor receptor gene (EGFR)-mutated advanced-stage non-small cell lung cancer …
growth factor receptor gene (EGFR)-mutated advanced-stage non-small cell lung cancer …